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Background: This study aimed to compare the distribution of Prostate Imaging Reporting and Data
System (PI-RADS) score and the diagnostic accuracy of magnetic resonance imaging (MRI)etargeted
biopsy and systematic biopsy between a Chinese and a Dutch cohort.
Materials and methods: Our study includes 316 men from Shanghai Changhai Hospital, China, and 266
men from the Erasmus University Medical Center, Rotterdam, the Netherlands. All men had a suspicion
for prostate cancer (PCa) and were offered an multiparametric MRI (mpMRI) scan.
Results: The distribution of the PI-RADS score was different between the two cohorts (P ¼ 0.008). In the
Chinese cohort of PI-RADS 3, the detection rate for high-grade PCa (Gleason 7) was 37.3% by sys-
tematic biopsy and 35.5% by MRI-targeted biopsy. The sensitivity of systematic biopsy was 0.80 for PCa
and 0.75 for high-grade PCa. MRI-targeted biopsy achieved slightly higher sensitivity for PCa (0.82) and
high-grade PCa (0.76). In the Dutch cohort of PI-RADS 3, the high-grade PCa detection rate was 44.4%
and 54.5% for systematic biopsy and MRI-targeted biopsy. The sensitivity of systematic biopsy was 0.93
for PCa and 0.81 for high-grade PCa. By MRI-targeted biopsy, the sensitivity was 0.85 for PCa and 0.97 for
high-grade PCa.
Conclusions: The distribution of the PI-RADS score was different with more PI-RADS 4/5 in the Chinese
cohort. Applying a PI-RADS 3 cutoff resulted in a favorable overall sensitivity. MRI-targeted biopsy
showed a higher sensitivity in the detection of high-grade PCa than systematic biopsy. The sensitivity of
MRI-targeted biopsy and systematic biopsy for both PCa and high-grade PCa in the Dutch cohort was
superior to those in the Chinese cohort.
© 2018 Asian Paciﬁc Prostate Society, Published by Elsevier Korea LLC. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Asia is known as one of the regions with the lowest prostate
cancer (PCa) incidence and mortality worldwide.1 However, theErasmus University Medical
am, the Netherlands.
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because of the introduction of prostate-speciﬁc antigen (PSA)
testing and subsequent prostate random biopsy.2 Currently in Asian
countries, especially in those developing regions, the proportion of
advanced PCa at diagnosis (>20%) is still much higher than that in
Europe.3,4 Although the level of overdiagnosis appears to be lower,
appropriate diagnostic methods are also essential in this rapidly
changing setting. Magnetic resonance imaging (MRI)etargeted bi-
opsy, applying visual estimation (cognitive fusion) system, MRI-
eultrasound (MRI-US) fusion system, or MRI in-bore-guided
system, achieves higher detection rate for clinically signiﬁcant PCa
using fewer cores than conventional transrectal ultrasound
(TRUS)eguided biopsy.5e8 Prostate Imaging Reporting and DataKorea LLC. This is an open access article under the CC BY-NC-ND license (http://
Imaging Reporting and Data System score and diagnostic accuracy of
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Table 1
Patient characteristics.
Characteristic Chinese cohort
(n ¼ 316)
Dutch cohort
(n ¼ 266)
P
Median IQR Median IQR
Age (year) 66.0 60.0e72.0 66.6 61.1e70.0 0.50
PSA (ng/mL) 9.7 6.7e15.7 11.1 8.4e17.7 0.001
Prostate volume (mL) 41.5 27.2e61.8 46.0 34.0e65.0 0.01
Number % Number % P
Positive DRE 58 18.4 56 21.1 0.41
Previous negative biopsy 57 18.0 256 96.2 <0.001
DRE, digital rectal examination; IQR, interquartile range; PSA, prostate-speciﬁc
antigen.
Table 2
The distribution of PI-RADS score in the two cohorts.
PI-RADS score Chinese cohort Dutch cohort
Number % Number %
Total number of men 316 100 266 100
PI-RADS 2 130 41.1 143 53.8
PI-RADS 3 47 14.9 28 10.5
PI-RADS 4 69 21.8 51 19.2
PI-RADS 5 70 22.2 44 16.5
PI-RADS, Prostate Imaging Reporting and Data System.
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(mpMRI) and can provide localization, characterization, and risk
stratiﬁcation for suspicious PCa lesions.9 However, these new
techniques are only available in very few Asian centers. Currently
available data on, e.g., predictive value of the PI-RADS score and
recommendations on how to use those in clinical practice are thus
mainly based on European data and might not be applicable to the
Asian setting.
In this study, we present data of mpMRI and biopsy outcome
from one Chinese and one Dutch center, comparing the distribution
of PI-RADS score and the diagnostic accuracy of MRI-targeted bi-
opsy, with the aim to assess potential differences in the positive
predictive value (PPV) of the PI-RADS score and the performance
characteristics of the MRI-targeted biopsy.
2. Materials and methods
2.1. Study population and mpMRI protocol
From September 2013 until December 2015, a total of 316 men
in Shanghai Changhai Hospital, Second Military Medical University
and 266 men in Erasmus University Medical Center, Rotterdam,
underwent an mpMRI scan because of a clinical suspicion of PCa
(no prior PCa diagnosis) based on an elevated PSA and/or abnormal
digital rectal examination (DRE).
In the Chinese cohort, MRIs were performed on a 3.0T system
(Magnetom Skyra; SiemensMedical Solutions, Erlangen, Germany).
The prostate MRI protocols included T1WI, triplanar (axial, sagittal,
and coronal) T2WI, diffusion-weighted imaging, and dynamic
contrast-enhanced imaging by using an 18-channel phased-array
coil. A single radiologist (Qingsong Yang) with 10 years of experi-
ence in prostate MRI analyzed the images and marked all the le-
sions according to the PI-RADS, version 1.0.
In the Dutch cohort, a 3.0T MR system (Discovery MR750;
General Electric Healthcare, Chicago, United States) with 32-
channel pelvic phased-array coil was used, and the prostate MRI
protocols also included T1WI, T2WI, diffusion-weighted imaging,
and dynamic contrast-enhanced imaging. All the MRIs were re-
ported by a single radiologist (Ivo G Schoots) withmore than 4 years
of experience in prostate mpMRI based on PI-RADS, version 1.0.
2.2. Systematic biopsy and MRI-targeted biopsy
In the Chinese cohort, the systematic biopsywas performedwith
a TRUS-guided approach (end-ﬁring ultrasound probe) using a me-
diannumberof 12 cores [interquartile range (IQR),12e12)becauseof
elevated PSA (4ng/ml) and/or abnormal DRE. MRI-targeted biopsy
was implementedusing cognitive fusion system, inwhich thebiopsy
operator used TRUS imaging to aim the suspicious lesions identiﬁed
at MRI. Themedian number of MRI-targeted biopsy core was 3 (IQR,
2e4). In the Dutch cohort, a TRUS-guided systematic biopsy was
performed with a median number of 12 cores (IQR, 10e12) using
end-ﬁringultrasoundprobebecause of elevated PSA (3ng/ml) and/
or abnormalDRE.MRI-US fusion system (UroStation; Koelis,Meylan,
France) was applied for MRI-targeted biopsy with amedian number
of 4 cores (IQR, 3e5) for PI-RADS 3 lesions. This system fuses the
MRI and real-time TRUS images based on software and allows
guiding biopsy on the TRUS images.8
2.3. Statistical analysis
Statistical analyses were performed by using SPSS for Windows
(Version 21.0; IBM Corp Armonk, NY, USA). The ManneWhitney U
test and the Chi-square test for trend were used to determine dif-
ferences between variables.Please cite this article in press as: Zhang K, et al., Distribution of Prostate
magnetic resonance imagingetargeted biopsy: comparison of an Asian
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3.1. Patient characteristics
The characteristics of the study population are shown in Table 1.
In the Chinese cohort of 316 men with a median age of 66.0 years
(IQR, 60.0e72.0), the median PSA value was 9.7 ng/ml (IQR,
6.7e15.7). Only 57 (18.0%) men had previous negative TRUS-guided
biopsies, and 58 (18.4%) men had a suspicious DRE. All the men
received an mpMRI scan, of whom 315 (99.7%) men underwent
systematic biopsy. Cognitive MRI-targeted biopsy was performed in
a total of 110 out of 186 (59%) men with an overall PI-RADS score
3 and additionally in 4 men with PI-RADS 2.
In the Dutch cohort of 266 men, the median age was 66.6 years
(IQR, 61.1e70.0), and the median PSA value was 11.1ng/ml (IQR,
8.4e17.6). Unlike theChinese cohort, a total of 256 (96.2%)menhada
previous negative biopsy. Comparable to the Chinese cohort, a total
of 56 (21.1%) men had a positive DRE result. A total of 115 (43.2%)
men underwent systematic biopsy. MRI-US fusion biopsy was per-
formed in all the men (N ¼ 123) with an overall PI-RADS score 3.3.2. Distribution of PI-RADS score
In the Chinese cohort, the PI-RADS score of the dominant lesion
was 2 in 130 (41.1%), 3 in 47 (14.9%), 4 in 69 (21.8%), and 5 in 70
(22.2%) men. In the Dutch cohort, these numbers were 2 in 143
(53.8%), 3 in 28 (10.5%), 4 in 51 (19.2%), and 5 in 44 (16.5%) men
(Table 2). The distribution of PI-RADS score varied between the two
cohorts (P¼ 0.008). In the Chinese cohort, the distributionwas also
different between the group of men with initial biopsy and previ-
ous negative biopsy (P ¼ 0.03) (Table 3).3.3. Positive predictive value of the PI-RADS for PCa and high-grade
PCa in MRI-targeted biopsy
In the Chinese cohort of 114 men with MRI-targeted biopsy, 66
men (57.9%) were diagnosed with PCa by MRI-targeted biopsy, ofImaging Reporting and Data System score and diagnostic accuracy of
and European cohort, Prostate International (2018), https://doi.org/
Table 3
The distribution of PI-RADS score between initial and previously negative biopsy in
the Chinese cohort.
Chinese cohort Initial biopsy Previous negative biopsy
Number % Number %
Total number of men 259 100 57 100
PI-RADS 2 116 44.8 14 24.6
PI-RADS 3 34 13.1 13 22.8
PI-RADS 4 55 21.2 14 24.6
PI-RADS 5 54 20.8 16 28.1
PI-RADS, Prostate Imaging Reporting and Data System.
K. Zhang et al. / Comparison of an Asian and European cohort 3whom 39 (34.2%) men had high-grade PCa (Gleason score 7). The
PPV of PI-RADS 3 was 60.0% for PCa (Table 4) and 35.5% for high-
grade PCa (Table 5).
In the Dutch cohort of 123 men with MRI-targeted biopsy, 89
(72.4%) cases of PCa and 67 (54.5%) cases of high-grade PCa were
detected. The PPV of PI-RADS 3 was 72.4% and 54.5% for PCa and
high-grade PCa, respectively (Tables 4 and 5).Table 5
The PPV of PI-RADS classiﬁcation for high-grade PCa in the two cohorts with MRI-target
Chinese cohort (n ¼ 114)
PI-RADS score (number) High-grade PCa PPV
PI-RADS 2 (4) 0 0
PI-RADS 3 (34) 9 35.3%
PI-RADS 4 (39) 15 61.5%
PI-RADS 5 (37) 15 78.4%
PI-RADS 3 (110) 39 35.5%
MRI, magnetic resonance imaging; PCa, prostate cancer; PI-RADS, Prostate Imaging Repo
Table 4
The PPV of PI-RADS classiﬁcation for PCa in the two cohorts with MRI-targeted biopsy.
Chinese cohort (n ¼ 114)
PI-RADS score (number) PCa PPV
PI-RADS 2 (4) 0 0
PI-RADS 3 (34) 13 38.2%
PI-RADS 4 (39) 26 66.7%
PI-RADS 5 (37) 27 73.0%
PI-RADS 3 (110) 66 60.0%
MRI, magnetic resonance imaging; PCa, prostate cancer; PI-RADS, Prostate Imaging Repo
Table 6
Comparison of outcomes between systematic biopsy and MRI-targeted biopsy in the Chi
Chinese cohort PI-RADS 1e2 (130)
PCa High-grade PCa
Systematic biopsy (130) 12 6
MRI-targeted biopsy (4) 0 0
MRI, magnetic resonance imaging; PCa, prostate cancer; PI-RADS, Prostate Imaging Repo
Table 7
Comparison of outcomes between systematic biopsy and MRI-targeted biopsy in the Du
Dutch cohort PI-RADS 1e2 (143)
PCa High-grade PCa
Systematic biopsy (52) 14 1
MRI-targeted biopsy (0) 0 0
MRI, magnetic resonance imaging; PCa, prostate cancer; PI-RADS, Prostate Imaging Repo
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targeted biopsy
In the Chinese cohort, 130 men with negative MRI results (PI-
RADS 1e2) underwent systematic biopsy; 12 (9.2%) cases of PCa
and 6 (4.6%) cases of high-grade PCa were detected. Among 186
men with PI-RADS 3, 185 men underwent systematic biopsy, and
69 (37.3%) cases of high-grade PCawere detected; 110men received
MRI-targeted biopsy, 39 of 110 were high-grade PCa (35.5%)
(Table 6).
In the Dutch cohort, 1 (1.9%) case of high-grade PCawas found in
menwith negative MRI results and systematic biopsy (N ¼ 52). The
positive rate for high-grade PCa among men with PI-RADS 3 was
44.4% (28/63) for systematic biopsy and 54.5% for MRI-targeted
biopsy (67/123) (Table 7).
For PI-RADS 1e2 lesions, there was no signiﬁcant difference in
the PCa detection by systematic biopsy between the Chinese and
Dutch cohorts. For PI-RADS 3 lesions, there was no signiﬁcant
difference in the high-grade PCa detection by systematic biopsy
between the two cohorts. In all the other subgroups, cancered biopsy.
Dutch Cohort (n ¼ 123)
PI-RADS score (number) High-grade PCa PPV
PI-RADS 2 (0) 0 0
PI-RADS 3 (28) 7 25%
PI-RADS 4 (51) 24 47.1%
PI-RADS 5 (44) 36 81.8%
PI-RADS 3 (123) 67 54.5%
rting and Data System; PPV, positive predictive value.
Dutch cohort (n ¼ 123)
PI-RADS score (number) PCa PPV
PI-RADS 2 (0) 0 0
PI-RADS 3 (28) 10 35.7%
PI-RADS 4 (51) 36 70.6%
PI-RADS 5 (44) 43 97.7%
PI-RADS 3 (123) 89 72.4%
rting and Data System; PPV, positive predictive value.
nese cohort.
Chinese cohort PI-RADS 3 (186)
PCa High-grade PCa
Systematic biopsy (185) 104 69
MRI-targeted biopsy (110) 66 39
rting and Data System.
tch cohort.
Dutch cohort PI-RADS 3 (123)
PCa High-grade PCa
Systematic biopsy (63) 50 28
MRI-targeted biopsy (123) 89 67
rting and Data System.
Imaging Reporting and Data System score and diagnostic accuracy of
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Table 9
Sensitivity of systematic biopsy and MRI-targeted biopsy in the Chinese cohort.
Prostate International xxx (2018) 1e64detection rate in the Dutch cohort was signiﬁcantly higher than in
the Chinese cohort (Table 8).Table 10
Sensitivity of systematic biopsy and MRI-targeted biopsy in the Dutch cohort.
Dutch cohort (115) Systematic biopsy
PCa/High-grade PCa Positive Negative
PI-RADS 1e2 (n ¼ 52) No biopsy 14/1 38/51
PI-RADS 3 (n ¼ 63): Positive 42/28 4/7
Chinese cohort (239) Systematic biopsy
PCa/High-grade Pca Positive Negative
PI-RADS 1e2 (n ¼ 130) No biopsy (accept for 4 men) 12/6 118/124
PI-RADS 3 (n ¼ 109):
(MRI-targeted biopsy)
Positive 49/26 16/13
Negative 14/12 30/58
MRI, magnetic resonance imaging; PCa, prostate cancer; PI-RADS, Prostate Imaging
Reporting and Data System.3.5. Sensitivity of Systematic biopsy and MRI-targeted biopsy
In the Chinese cohort, 109 men with PI-RADS 3 underwent
systematic plus MRI-targeted biopsy (combined biopsy), in which
systematic biopsy detected 63 PCa and 38 high-grade PCa and MRI-
targeted biopsy detected 65 PCa and 39 high-grade PCa. In the
group of menwith PI-RADS 3, the sensitivity of systematic biopsy
was 0.80 for PCa and 0.75 for high-grade PCa. By contrast, MRI-
targeted biopsy achieved slightly higher sensitivity for PCa (0.82)
and high-grade PCa (0.76) (Table 9).
In the Dutch cohort of 63 men with PI-RADS 3 who received
combined biopsy, the sensitivity of systematic biopsy was 0.93 for
PCa and 0.81 for high-grade PCa. By MRI-targeted biopsy, the
sensitivity was 0.85 for PCa and 0.97 for high-grade PCa (Table 10).(MRI-targeted biopsy) Negative 8/1 9/27
MRI, magnetic resonance imaging; PCa, prostate cancer; PI-RADS, Prostate Imaging
Reporting and Data System.4. Discussion
Multiparametric MRI with PI-RADS grading and MRI-targeted
biopsy have shown great potential to improve diagnostic accu-
racy of clinically signiﬁcant PCa in multiple European and North
American studies.5,10e16 PCa incidence and mortality differ greatly
between European and Asian countries,17 suggesting that tumor
characteristics might vary among races and regions. In both cohorts
of this study, PI-RADS showed favorable predictive value for PCa
and high-grade PCa although the distribution of PI-RADS was
different between the two cohorts. In both cohorts, MRI-targeted
biopsy showed high sensitivity for high-grade PCa in men with
PI-RADS 3.
To our knowledge, this study is the ﬁrst to analyze the distri-
bution of PI-RADS score between European and Asian populations.
PI-RADS was developed by experts from the European Society of
Urogenital Radiology in 2012, with the aim to build up clinical
guidelines and standards for mpMRI.18 Nowadays, it has been
widely used in prostate MRI diagnosis worldwide. In our study,
based on 582 men with a suspicion of PCa and who underwent
mpMRI scans, the distribution of PI-RADS varied between the two
cohorts, with more PI-RADS 3/4/5 in the Chinese cohort. However,
this variation could at least in part be explained by the difference in
biopsy history. Most Dutch men had a previous negative biopsy,
whereas only 18% of Chinese men had a previous negative biopsy.
This effect of biopsy history is conﬁrmed in the Chinese data where
therewas a difference in PI-RADS distribution between the ﬁrst and
repeat biopsy. This might be a reﬂection of the practice in European
countries. High proportion of men with a suspicion of PCa and
previous negative biopsy underwent mpMRI and subsequent MRI-
targeted biopsy following the European Association of Urology
guidelines. In these guidelines, MRI-targeted biopsy is not recom-
mended for initial biopsy. Conversely, there is no guideline
regarding the MRI-targeted biopsy in China and most AsianTable 8
Comparison of outcomes between systematic biopsy and MRI-targeted biopsy in the Ch
Prostate biopsy Detection rate
Systematic biopsy for PCa in PI-RADS 1e2 lesions
Systematic biopsy for high-grade PCa in PI-RADS 1e2 lesions
Systematic biopsy for PCa in PI-RADS 3 lesions
Systematic biopsy for high-grade PCa in PI-RADS 3 lesions
MRI-targeted biopsy for PCa in PI-RADS 3 lesions
MRI-targeted biopsy for high-grade PCa in PI-RADS 3 lesions
MRI, magnetic resonance imaging; PCa, prostate cancer; PI-RADS, Prostate Imaging Repo
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the access of MRI.
Our study results indicated that PI-RADS 3 could be used as a
cutoff for MRI-targeted biopsy in a Chinese population. Currently,
also in Europe, there is no speciﬁc PI-RADS score cutoff recom-
mended for biopsy as other factors such as laboratory ﬁndings,
clinical history, and local preferences should also be considered in
decision-making.18,19 In the Chinese cohort of our study, the PPV of
PI-RADS3 for PCawas 60.0% for PCa and 35.5% for high-grade PCa,
and if it was set as the cutoff for biopsy, no case of PCa would be
missed. As comparison, in an Irish study, 81 prostatic areas un-
derwent MRI-targeted biopsy in 52 patients. The PPV of overall PI-
RADS scores of 3, 4, and 5 was 10.6%, 44%, and 100%, respectively.
PI-RADS 3 showed a PPV of 30.9% for PCa.12 A Japanese study of
288 men also indicated that the PPV of PI-RADS 3 was 41.7% and
37.5% for PCa and high-grade PCa, respectively.20 Our study ﬁndings
compare favorably with previous series, evaluating the perfor-
mance of MRI-targeted biopsy in men with mixed indications for
biopsy, but are comparable between our Chinese and Dutch co-
horts. Our results demonstrate the potential of PI-RADS in selecting
men who would most beneﬁt from MRI-targeted biopsy and in
avoiding unnecessary biopsies.
A topic of debate is the necessity of performing systematic
biopsy in men with a negative MRI. In our study, 95.4% of biopsies
could be saved in men with PI-RADS 1e2 in the Chinese cohort,
and only 6 cases of high-grade PCa (4.6%) would be missed. In the
Dutch cohort, only 1 case of high-grade PCa would be missed, and
98.1% of systematic biopsies could have been avoided in men with
negative MRI. Comparable data from an Austrian study with 73
men showed that the PI-RADS score was correlated with PCa
incidence and aggressiveness. A proportion of 31% of men withinese cohort and the Dutch cohort.
in the Chinese cohort Detection rate in the Dutch cohort P
9.2% 26.9% 0.002
4.6% 1.9% 0.394
56.2% 79.4% 0.001
37.3% 44.4% 0.315
60% 72.4% 0.046
35.5% 54.5% 0.004
rting and Data System.
Imaging Reporting and Data System score and diagnostic accuracy of
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showed that men with negative lesion on MRI only had a risk of
2% for high-grade PCa.22 However, an American study reviewed
84 men without suspicious regions on MRI or only with PI-RADS
1e2 lesions who underwent systematic biopsy. Overall, 22
(26.2%) cases of PCa were detected, including 11 (13.1%) high-
grade PCa.23 Although further evaluation is needed, based on
our study, including 185 men with negative MRI who underwent
systematic biopsy, it could be concluded that further risk strati-
ﬁcation, especially considering retesting intervals in this group, is
warranted.
In the Chinese cohort of 186 men with PI-RADS 3, systematic
biopsy detected 104 PCa (56.2%) including 69 high-grade PCa
(37.3%). Also in this subgroup, 109 men underwent systematic bi-
opsy plus MRI-targeted biopsy, and 79 PCa (72.5%) including 51
high-grade PCa (46.8%) were detected. In a French study of 555men
undergoing 10e12 cores systematic biopsy plus targeted biopsy,
252 (71.8%) PCa were detected among 351 men with positive MRI,
and systematic biopsy alone could detect 236 (67.2%) PCa.24 In a
Korean prospective study, the outcomes of 44 menwith systematic
biopsy plus MRI-targeted biopsy and 41 men with systematic bi-
opsy were compared.25 It showed that combined biopsy group had
a signiﬁcantly higher PCa detection rate and positive core rate than
systematic biopsy group.25 Based on our study and other available
data, combined biopsy seems to achieve optimal PCa and high-
grade PCa detection rate among men with PI-RADS 3.
In this study, MRI-targeted biopsy showed high sensitivity for
PCa and high-grade PCa. In a European systematic review, 1,926
men with a positive MRI from 16 studies were included with the
aim to compare MRI-targeted biopsy with systematic biopsy. MRI-
targeted biopsy showed higher sensitivity in overall PCa detection
(85% vs. 81%) and signiﬁcant PCa detection (91% vs. 76%).11 In the
Chinese cohort of our study, MRI-targeted biopsy achieved higher
sensitivity in the detection of PCa (82% vs. 80%) and high-grade PCa
(76% vs. 75%) compared with systematic biopsy. In the Dutch
cohort, the sensitivity comparison was 85% versus 93% for PCa and
97% versus 81% for high-grade PCa. It is noteworthy that MRI-
targeted biopsy was comparable with systematic biopsy in overall
PCa detection; however, in high-grade PCa detection, MRI-targeted
biopsy had the distinct superiority, which was consistent with the
conclusions of the European study.11
The strength of this study lies in the fact that it includes two
cohorts from different area (continents) and both represent a true
clinical situation.
Our study is limited by its retrospective nature. Most men in the
Dutch cohort have previously negative biopsies, but in the Chinese
cohort, 82% of men have no history of biopsy. It reﬂected the real
practice in European countries because MRI-targeted biopsy is only
recommended for repeat biopsy according to the European Asso-
ciation of Urology guidelines. In addition, the MRI-targeted biopsy
procedures of the two cohorts are different. However, a recently
published study showed that there was no signiﬁcant difference in
the performance of MRI-US fusion biopsy compared with cognitive
fusion biopsy in the detection rate of overall PCa and clinically
signiﬁcant PCa.26
In conclusion, the distribution of the PI-RADS score was
different, largely reﬂecting daily clinical practice. In both cohorts,
PI-RADS 3 achieves favorable PPV for detecting PCa and high-
grade PCa, and there was very small beneﬁt when performing
systematic biopsy in men with PI-RADS 1e2. MRI-targeted biopsy
plus systematic biopsy however achieved the optimal PCa and
high-grade PCa detection rate among men with PI-RADS 3. MRI-
targeted biopsy showed higher sensitivity in the detection of
high-grade PCa than systematic biopsy in both cohorts. The PI-
RADS system seems to be applicable in an Asian setting.Please cite this article in press as: Zhang K, et al., Distribution of Prostate
magnetic resonance imagingetargeted biopsy: comparison of an Asian
10.1016/j.prnil.2018.10.001Conﬂicts of interest
The authors have no conﬂicts of interest or ﬁnancial disclosures
to declare.References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer
statistics, 2012. CA Cancer J Clin 2015;65(2):87e108.
2. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, et al. In-
ternational variation in prostate cancer incidence and mortality rates. Eur Urol
2012;61(6):1079e92.
3. Chen R, Ren S, Yiu MK, Fai NC, Cheng WS, Ian LH, et al. Prostate cancer in Asia: a
collaborative report. Asian J Urol 2014;1(1):15e29.
4. Ito K. Prostate cancer in Asian men. Nat Rev Urol 2014;11(4):197e212.
5. Pokorny MR, de Rooij M, Duncan E, Schroder FH, Parkinson R, Barentsz JO, et al.
Prospective study of diagnostic accuracy comparing prostate cancer detection
by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) im-
aging with subsequent MR-guided biopsy in men without previous prostate
biopsies. Eur Urol 2014;66(1):22e9.
6. Wysock JS, Rosenkrantz AB, Huang WC, Stifelman MD, Lepor H, Deng FM, et al.
A prospective, blinded comparison of magnetic resonance (MR) imaging-
ultrasound fusion and visual estimation in the performance of MR-targeted
prostate biopsy: the PROFUS trial. Eur Urol 2014;66(2):343e51.
7. Pinto PA, Chung PH, Rastinehad AR, Baccala Jr AA, Kruecker J, Benjamin CJ, et al.
Magnetic resonance imaging/ultrasound fusion guided prostate biopsy im-
proves cancer detection following transrectal ultrasound biopsy and correlates
with multiparametric magnetic resonance imaging. J Urol 2011;186(4):
1281e5.
8. Bjurlin MA, Mendhiratta N, Wysock JS, Taneja SS. Multiparametric MRI and
targeted prostate biopsy: improvements in cancer detection, localization, and
risk assessment. Cent Eur J Urol 2016;69(1):9e18.
9. Turkbey B, Choyke PL. PIRADS 2.0: what is new? Diagn Interv Radiol
2015;21(5):382e4.
10. Siddiqui MM, Rais-Bahrami S, Turkbey B, George AK, Rothwax J, Shakir N, et al.
Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided
biopsy for the diagnosis of prostate cancer. JAMA 2015;313(4):390e7.
11. Schoots IG, Roobol MJ, Nieboer D, Bangma CH, Steyerberg EW, Hunink MG.
Magnetic resonance imaging-targeted biopsy may enhance the diagnostic ac-
curacy of signiﬁcant prostate cancer detection compared to standard trans-
rectal ultrasound-guided biopsy: a systematic review and meta-analysis. Eur
Urol 2015;68(3):438e50.
12. NiMhurchu E, O'Kelly F, Murphy IG, Lavelle LP, Collins CD, Lennon G, et al.
Predictive value of PI-RADS classiﬁcation in MRI-directed transrectal ultra-
sound guided prostate biopsy. Clin Radiol 2016;71(4):375e80.
13. Portalez D, Mozer P, Cornud F, Renard-Penna R, Misrai V, Thoulouzan M, et al.
Validation of the European Society of Urogenital Radiology scoring system for
prostate cancer diagnosis on multiparametric magnetic resonance imaging in a
cohort of repeat biopsy patients. Eur Urol 2012;62(6):986e96.
14. Futterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A,
et al. Can clinically signiﬁcant prostate cancer be detected with multi-
parametric Magnetic resonance imaging? A systematic review of the literature.
Eur Urol 2015;68(6):1045e53.
15. Nam RK, Wallis CJ, Stojcic-Bendavid J, Milot L, Sherman C, Sugar L, et al. A pilot
study to evaluate the role of magnetic resonance imaging for prostate cancer
screening in the general population. J Urol 2016;196(2):361e6.
16. Meng X, Rosenkrantz AB, Mendhiratta N, Fenstermaker M, Huang R, Wysock JS,
et al. Relationship between prebiopsy multiparametric magnetic resonance
imaging (MRI), biopsy indication, and MRI-ultrasound Fusion-targeted prostate
biopsy outcomes. Eur Urol 2016;69(3):512e7.
17. Wong MC, Goggins WB, Wang HH, Fung FD, Leung C, Wong SY, et al. Global
incidence and mortality for prostate cancer: analysis of temporal patterns and
trends in 36 countries. Eur Urol 2016 Nov;70(5):862e74.
18. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, et al. ESUR
prostate MR guidelines 2012. Eur Radiol 2012;22(4):746e57.
19. Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-
RADS Prostate imaging - reporting and data system: 2015, Version 2. Eur Urol
2016;69(1):16e40.
20. Washino S, Okochi T, Saito K, Konishi T, Hirai M, Kobayashi Y, et al. Combi-
nation of PI-RADS score and PSA density predicts biopsy outcome in biopsy
naive patients. BJU Int 2017 Feb;119(2):225e33.
21. Junker D, Schafer G, Edlinger M, Kremser C, Bektic J, Horninger W, et al.
Evaluation of the PI-RADS scoring system for classifying mpMRI ﬁndings in
men with suspicion of prostate cancer. BioMed Res Int 2013;2013:252939.
22. Wysock JS, Mendhiratta N, Zattoni F, Meng X, Bjurlin M, Huang WC, et al.
Predictive value of negative 3T multiparametric magnetic resonance imaging
of the prostate on 12-core biopsy results. BJU Int 2016;118(4):515e20.
23. Wang RS, Kim EH, Vetter JM, Fowler KJ, Shetty AS, Mintz AJ, et al. Determi-
nation of the role of negative magnetic resonance imaging of the prostate in
clinical practice: Is biopsy still necessary? Urology 2017 Apr;102:190e7.
24. Haffner J, Lemaitre L, Puech P, Haber GP, Leroy X, Jones JS, et al. Role of mag-
netic resonance imaging before initial biopsy: comparison of magneticImaging Reporting and Data System score and diagnostic accuracy of
and European cohort, Prostate International (2018), https://doi.org/
Prostate International xxx (2018) 1e66resonance imaging-targeted and systematic biopsy for signiﬁcant prostate
cancer detection. BJU Int 2011;108(8 Pt 2):E171e8.
25. Park BK, Park JW, Park SY, Kim CK, Lee HM, Jeon SS, et al. Prospective evalu-
ation of 3-T MRI performed before initial transrectal ultrasound-guided pros-
tate biopsy in patients with high prostate-speciﬁc antigen and no previous
biopsy. AJR Am J Roentgenol 2011;197(5):W876e81.Please cite this article in press as: Zhang K, et al., Distribution of Prostate
magnetic resonance imagingetargeted biopsy: comparison of an Asian
10.1016/j.prnil.2018.10.00126. Wegelin O, van Melick HH, Hooft L, Bosch JL, Reitsma HB, Barentsz JO, et al.
Comparing three different techniques for magnetic resonance imaging-
targeted prostate biopsies: a systematic review of in-bore versus magnetic
resonance imaging-transrectal ultrasound fusion versus cognitive registration.
Is there a preferred technique? Eur Urol 2017;71(4):517e31.Imaging Reporting and Data System score and diagnostic accuracy of
and European cohort, Prostate International (2018), https://doi.org/
